Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Lenalidomide in Relapsed/Refractory NHL and HD
NCT03015896Phase 2Completed
- Start
- Feb 2017
- Primary completion
- Aug 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, lenalidomide in non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL). Started Feb 2017; status: completed.
02
Drugs
nivolumablenalidomide
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03015896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03015896.